Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS AnGes MG to Resume Collategene Development for Critical Limb Ischemia Treatment: President Yamada
November 29, 2013
-
REGULATORY MHLW Proposes to “Institutionalize” New Drug Premium; Equivocal Wording Draws Fire at CSIMC
November 28, 2013
-
BUSINESS President Hasegawa of Takeda Confident About Achieving Targets in Midterm Growth Strategy; Company to Appoint CIO
November 28, 2013
-
BUSINESS Azilva Tops Physician “Mind Share” Ranking in GP, HP Markets in October: New Survey
November 27, 2013
-
BUSINESS Eisai to Take Over Marketing Rights for Gliadel from Nobelpharma
November 27, 2013
-
ACADEMIA All Clinical Studies Should Follow GCP Requirements: Ex-AZ Chairman Kato
November 26, 2013
-
BUSINESS Farmorubicin Approved for Additional Dosage and Administration for Hepatic Cancer: Pfizer Japan
November 26, 2013
-
BUSINESS AZ Aims to Maintain Presence in Oncology Field Via Partnerships until Launch of New Drugs
November 25, 2013
-
BUSINESS Takeda Deploys Cardiovascular, Diabetes Sales Reps for Comprehensive Detailing Activities for Lifestyle Diseases
November 22, 2013
-
BUSINESS Japan Diovan Sales Down 15.7% in July-September: IMS
November 22, 2013
-
REGULATORY JGA President Opposes 50% Rule for Generics, CSIMC Subcommittee Members Disagree
November 21, 2013
-
BUSINESS Japan Now Part of Global PIII Clinical Study for MLN9708: Takeda
November 21, 2013
-
BUSINESS US Pfizer Plans Simultaneous, Global Filing of Five Biosimilars, Eyes Japan Biosimilar Market Entry
November 20, 2013
-
ACADEMIA JAMS’ Draft of Revised Guidelines Ups Ante for COI Disclosures in Clinical Trials
November 19, 2013
-
REGULATORY PAFSC’s 1st Committee on Drugs to Review Astellas’s SGLT-2 Inhibitor Ipragliflozin on Nov. 29
November 19, 2013
-
BUSINESS Takeda, Eisai Earnings Show Signs of Bottoming Out, on Path to Recovery
November 18, 2013
-
BUSINESS Sales of Major Japanese Drug Makers Soar 8.1% on Weak Yen, Steady Japan Business
November 15, 2013
-
REGULATORY Health Ministry Proposes to Set First Generic Prices at Half of Brand Name Drug Prices
November 14, 2013
-
BUSINESS Otsuka Holdings Notches Double-Digit Sales Growth in April-September, Weaker Yen Comes as Boon
November 14, 2013
-
BUSINESS Generic Market Continues to Grow, Three Generic-Only Makers’ Sales Up 8.8%
November 13, 2013
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…